“Collaboration is essential to bring the benefits of molecular medicine research to all our societies”
Tuesday 2 May, the Nordic nodes of the EMBL Partnership resigned their commitment to each other and the partnership for 10 more years. With the new signing, research in the field of molecular medicine will continue to have the best prerequisites for developing disease-targeted medicine with critical importance for human health.
The new speaker of the partnership Oliver Billker from The University of Umeå draws the lines for future collaboration:
“Molecular medicine affects all our lives, but it is a fast-moving research field. No Nordic country can individually excel in all its aspects. In the future, we want to broaden and deepen our interactions further. We see many ways to achieve this, for instance, by inspiring and funding collaborative research, linking our training activities even more, and networking our complementary research infrastructure further. These interactions facilitate a valuable cross-fertilization of ideas that enhances the quality of our research and training endeavors”.
During the last ten years, numerous achievements have sprung from the partnership, with one of the biggest being a Nobel Prize awarded to Emmanuelle Charpentier, a former Group Leader at MIMS and the University of Umeå. A great example of the Nordic fostering the next generation of researchers of molecular medicine.
The anchoring in the EMBL model to recruit early-career researchers is one of the aspects that makes the partnership unique and enables the Nordic to attract and develop global expertise within this field of research. As a result, the Nordic Partnership facilitates the impact and reach of Nordic science throughout Europe and the world.
We look forward to what the next 10 years will bring to the Nordic, to Europe, and to new discoveries in future medicine.